Education
About Us
Working with TipRanks
Follow Us
Pharmaxis Ltd (AU:SNT)
ASX:SNT
Total Valuation
Pharmaxis Ltd has a market cap or net worth of AU$82.83M. The enterprise value is AU$23.38M.
Market CapAU$82.83M
Enterprise ValueAU$23.38M
Share Statistics
Pharmaxis Ltd has 1,624,178,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,624,178,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pharmaxis Ltd’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Pharmaxis Ltd is ―. Pharmaxis Ltd’s PEG ratio is ―.
PE Ratio―
PS Ratio13.13
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Pharmaxis Ltd had revenue of ― and earned -1.94M in profits. Earnings per share was ―.
Revenue―
Gross Profit7.43M
Operating Income-22.77M
Pretax Income―
Net Income-1.94M
EBITDA-12.15M
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Pharmaxis Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.57
52-Week Price Change150.00%
50-Day Moving Average0.07
200-Day Moving Average0.05
Relative Strength Index (RSI)25.82
Average Volume (3m)3.93M
Important Dates
Pharmaxis Ltd upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateFeb 26, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Pharmaxis Ltd as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Pharmaxis Ltd has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Pharmaxis Ltd EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Pharmaxis Ltd has ― in cash and marketable securities with 9.25M in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt9.25M
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Pharmaxis Ltd is AU$0.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$0.25
Price Target Upside400.00% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―